Fresenius Group Overview

Results Center

To archive

Q3/19 Results

Fresenius confirms guidance after solid third quarter
  • Strong organic sales growth across all business segments
  • Growth investments proceeding according to plan
  • Fresenius Kabi’s excellent Emerging Markets growth partially offsets softer development in North America
  • Fresenius Helios showing excellent organic sales growth across all regions
  • Fresenius Medical Care with record growth in home dialysis in North America

Selected Key Figures Q3/19

key figures

1 On a comparable basis

2 In constant currency

3 Net income attributable to shareholders of Fresenius SE & Co. KGaA